Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of ENT201 in Allergic and Vasomotor Rhinitis
jRCT2051260080Phase 3Recruiting
- Sponsor
- CEOLIA Pharma
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and non-allergic rhinitis (NAR) comparing ENT201 intranasal arm with Placebo intranasal arm (2 arms). Started Jun 2026; status: recruiting.
02
Drugs
ipratropium bromide
03
Conditions
allergic rhinitis (AR)non-allergic rhinitis (NAR)
Beyond the preview
Go deeper on jRCT2051260080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260080.